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Compromised astrocyte function and
survival negatively impact neurons in
infantile neuronal ceroid lipofuscinosis
Jenny Lange1, Luke J. Haslett2, Emyr Lloyd-Evans2, Jennifer M. Pocock3, Mark S. Sands4, Brenda P. Williams1†
and Jonathan D. Cooper1,5,6*†
Abstract
The neuronal ceroid lipofuscinoses (NCLs) are the most common cause of childhood dementia and are invariably
fatal. Early localized glial activation occurs in these disorders, and accurately predicts where neuronal loss is most
pronounced. Recent evidence suggests that glial dysfunction may contribute to neuron loss, and we have now
explored this possibility in infantile NCL (INCL, CLN1 disease). We grew primary cultures of astrocytes, microglia, and
neurons derived from Ppt1 deficient mice (Ppt1−/−) and assessed their properties compared to wildtype (WT)
cultures, before co-culturing them in different combinations (astrocytes with microglia, astrocytes or microglia with
neurons, all three cell types together). These studies revealed that both Ppt1−/− astrocytes and microglia exhibit a
more activated phenotype under basal unstimulated conditions, as well as alterations to their protein expression
profile following pharmacological stimulation. Ppt1- /− astrocytes also displayed abnormal calcium signalling and an
elevated cytoplasmic Ca2+ level, and a profound defect in their survival. Ppt1−/− neurons displayed decreased
neurite outgrowth, altered complexity, a reduction in cell body size, and impaired neuron survival with prolonged
time in culture. In co-cultures, the presence of both astrocytes and microglia from Ppt1−/− mice further impaired the
morphology of both wild type and Ppt1−/− neurons. This negative influence was more pronounced for Ppt1−/−
microglia, which appeared to trigger increased Ppt1−/− neuronal death. In contrast, wild type glial cells, especially
astrocytes, ameliorated some of the morphological defects observed in Ppt1−/− neurons. These findings suggest
that both Ppt1−/− microglia and astrocytes are dysfunctional and may contribute to the neurodegeneration
observed in CLN1 disease. However, the dysfunctional phenotypes of Ppt1−/− glia are different from those present
in CLN3 disease, suggesting that the pathogenic role of glia may differ between NCLs.
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Introduction
The neuronal ceroid lipofuscinoses (NCLs, or Batten
disease) are a large group of inherited lysosomal storage
disorders, each caused by mutations in an individual
gene [8, 32]. The age of onset and rate of disease pro-
gression are determined by which gene is deficient, and
which mutation is present within that gene. The NCLs
are collectively the largest cause of childhood dementia
and share a range of similar clinical features, including
loss of vision, epileptic seizures, and declines in mental
and motor abilities, all invariably leading to premature
death [2, 9, 50].
Despite recent advances in the treatment of late
infantile NCL (CLN2 disease) via enzyme replacement
therapy [30], the other forms of NCL all remain untreat-
able. This includes infantile NCL (INCL or CLN1
disease), an earlier onset and more rapidly progressing
form of NCL, which is caused by a mutation in the
CLN1/PPT1 gene (Vesa et al., 1995; [5, 21]). However, it
remains unclear how deficiency in palmitoyl protein
thioesterase-1 (PPT1), the lysosomal enzyme encoded by
this gene results in the devastating neurodegenerative
impact upon the brain that typifies CLN1 disease.
The generation of an INCL mouse model (Ppt1−/− mice)
[17] has made it possible to study the consequences of
PPT1 deficiency [3, 23, 29], and test a range of pre-clinical
interventions [19]. These mice display a progressive CLN1
disease-like phenotype, with well-defined declines in be-
havioural and neurological performance, and degenerative
changes that are most pronounced within the thalamocor-
tical system and cerebellum. Characteristically these mice
display a profound activation of both microglia and astro-
cytes, which precedes neuron loss [23, 29]. The regional
localization of this glial activation correlates closely with
distribution of subsequent neuron loss, leading to the sug-
gestion that these events may be causally related.
Rather than their traditional supportive role, evi-
dence is emerging that both astrocytes and microglia
can directly contribute to neuron loss in a variety of
disease states [25]. Amongst these are several lyso-
somal storage disorders [11, 41, 48], including the ju-
venile form of NCL, CLN3 disease or JNCL [35, 51].
We have recently shown via primary cultures derived
from Cln3 deficient mice that astrocytes and micro-
glia are both dysfunctional, and when co-cultured can
harm healthy neurons and kill Cln3 deficient neurons,
suggesting a direct influence of glia upon the patho-
genesis of this form of NCL [35].
The extent of glial activation is much more pronounced
in CLN1 disease, but as longitudinal studies show [23, 29],
still accurately predicts the sites where neuron loss subse-
quently occurs. This raises the question of what the role
of glia in this most profoundly neurodegenerative form of
NCL may be. As a first step to resolving this question, we
derived primary cultures of either astrocytes or microglia
from Ppt1−/− mice, and compared their properties and
response to stimulation to those derived from wild type
controls.
This in vitro study revealed a range of abnormal pheno-
types different to those seen in Cln3 disease glia [35].
Ppt1−/− astrocytes and microglia both appeared more acti-
vated than WT cells under basal unstimulated culture con-
ditions. However, most notable was a profound defect in
the survival of Ppt1−/− astrocytes, which also displayed
marked dysregulation of intracellular calcium handling, and
subsequent death by apoptosis. Primary cortical neuron
cultures from Ppt1−/− mice displayed abnormal dendritic
morphology and impaired survival, especially of interneu-
rons. Using a co-culture system wild type glia ameliorated
these neuronal phenotypes, whereas Ppt1−/− astrocytes pre-
dominantly impaired the morphology of WT neurons, and
Ppt1−/− microglia appeared to trigger increased Ppt1−/−
neuronal death via apoptosis. These effects were more pro-
nounced in mixed glial co-cultures when both Ppt1−/−
astrocytes and microglia were grown together with
neurons. Taken together, these data suggest that the
dysfunction of astrocytes and microglia in CLN1 disease is
detrimental to neurons and may lead to their loss.
Materials and methods
Animals
Homozygous Ppt1 deficient (Ppt1−/−) mice were origin-
ally created through the deletion of the last exon in the
Ppt1 coding sequence [17], and were subsequently bred
for at least 10 generations onto a C57/BL/6 J back-
ground [16]. The colony was maintained together with a
colony of C57/BL/6 J wild type (WT) control mice
originally derived from the crossing of heterozygous
Ppt1+/− mice. All animal maintenance and experimental
procedures were carried out according to the UK Scien-
tific Procedures (Animals) Act (1986).
Tissue culture
Preparation of glial cultures
Mixed glial cells were isolated from post-natal day 1–5
(P1-P5) Ppt1−/− or WT mouse cerebral cortices, as pre-
viously described [31, 35]. Cultures reached confluence
after 10–14 days, at which point they were composed of
a base layer of non-dividing astrocytes and an upper
layer of microglia as well as a few oligodendrocytes. To
generate astrocyte cultures, microglia were removed by
shaking cultures at 180 rpm for 10–12 h in a humidified
incubator (5% CO2, 37C, ([31]). The remaining astrocyte
monolayer was treated with cytosine arabinoside (Ara-C)
for 7 days to abolish any remaining dividing cells. Astro-
cytes for immunofluorescence staining experiments were
plated at 1.5 × 104 cells per well onto poly-D-lysine
(PDL, 25μg/ml, Sigma) coated glass coverslips in 24 well
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plates. For all functional assays unless otherwise de-
scribed, astrocytes were plated at 14.25 × 104 cells per
well onto PDL coated 6 well plates and kept in
phenol-red-free DMEM supplemented with 4500 mg/L
glucose (Sigma, Poole, UK), to prevent the presence of
phenol red from providing a background interference.
Microglial cultures
Microglial cultures were isolated from mixed glial cul-
tures using the shaking method described above [31, 35].
The harvested cells were resuspended in RPMI 1640
supplemented with 5% FBS, P/S, 2 mM L-Glutamine,
macrophage colony-stimulating factor and granulate
macrophage colony-stimulating factor, and consequently
plated on PDL coated (as above) 1.5 cm coverslips
placed in 24 well plates. They were maintained for
5 days, before growth factors were removed for a further
two days. At the start of all experiments, all glial cultures
had been maintained for approximately 21 days, yielding
cultures of > 99% purity.
Microglia for co-cultures
Due to the difficulty of detaching microglia from PDL
coated plastic surfaces, a different method was used to gen-
erate microglia for co-culturing with either astrocytes or
neurons. These microglia were prepared from P3-P5
Ppt1−/− or WT mouse cerebral cortices, initially generating
mixed glial cultures as described above. Conditioned
medium from these mixed cultures was collected and cul-
tures subsequently incubated at 37 °C with 1 mL/well of
Trypsin-EDTA (0.5mgml-1, Sigma). After 45 min the cell
monolayer, consisting primarily of astrocytes, was removed
along with the supernatant and discarded. The remaining
microglial cells were washed before being incubated in a
1:1 mixture of conditioned and fresh medium. These
microglial cultures were ready to be used in co-culture
experiments after 48 h, when they were removed from
wells using 0.5 ml Accutase (Sigma) and a cell scraper
(Corning). Microglia were then added to co-cultures at a
concentration of 50 × 104 cells/ml per well.
Neuronal cultures
Neuronal cultures were generated from P0 Ppt1−/− and
WT mouse cortices as previously described [35] and
plated on PDL-coated 13 mm coverslips placed in 24
well plates at a concentration of 15 × 104 cells/cm2.
These cultures were maintained for 7, 9 or 14 days.
Co-cultures
Neurons to be grown in co-cultures were plated onto
19 mm diameter coverslips in placed in 12 well plates at
a concentration of 15 × 104 cells/cm2. After 7 days, glial
cells previously maintained in culture for 21 days were
added to these neurons at a density of 100 × 104 cells/ml
for astrocytes or mixed glia, and 50 × 104 cells/ml for
microglia. Additional coverslips plated with just glia (ei-
ther astrocytes, microglia or of mixed glia), or only neu-
rons were set up as control conditions. Co-cultures were
grown for an additional 2 or 7 days before commencing
analysis, making the neuronal cultures used in these
experiments 9 or 14 days old. The composition of 14 day
old neuronal cultures was assessed using cell type-specific
phenotypic markers, as described below.
Pharmacological activation of glial cells Astrocytes
were stimulated with lipopolysaccharide (LPS, 1 μg/ml
LPS, Sigma) and interferon-gamma (IFN-γ, 100 U/ml,
Thermo Scientific) for 24 or 48 h, while microglia were
stimulated with LPS alone for either 6 or 24 h [35].
Mixed glial cultures were stimulated for 24 h using both
stimuli.
Immunofluorescence staining Cultures were fixed in
4% PFA and stained as previously described [35] and
across all experiments, nuclei were counterstained with
DAPI. Cell type-specific markers were used to assess
culture composition, with glial fibrillary acidic protein
(GFAP, Rabbit polyclonal, 1:500, Dako) being used to
identify astrocytes, Cluster of Differentiation 68 (CD68,
Rat monoclonal, 1:250, Serotec) to identify microglia,
Map2 MAP2 (mouse monoclonal, 1:1000, Abcam) to
identify neurons and O4 (Mouse monoclonal, 1:100,
Covance) to identify oligodendrocytes. Cytoskeletal com-
ponents were examined by staining cultures with Phal-
loidin, α- and β-tubulin (monoclonal and polyclonal
antibodies respectively, both from Sigma and used at
1:1000). All secondary antibodies were used 1:1000 and
obtained from Invitrogen. Coverslips were mounted using
Fluoromount G and stained cells were visualized using a
Zeiss AxioImager Z1 microscope (Carl Zeiss, Ltd) and im-
ages captured with a monochrome AxioCamMR3 camera,
using AxioVision 4.8 Imaging software.
Morphological Assessment Images of 10 random fields
were taken per coverslip of GFAP stained,
non-overlapping astrocytes and soma size was measured
using ImageJ (National Institutes of Health, Bethesda,
MD). Neuron soma size and neurite length were mea-
sured using ImageJ on images of 10 random fields per
coverslip in neuronal cultures or 20 random fields per
coverslip in co-cultures. The length of the longest neur-
ite was obtained per neuron; as well as mean neurite
length per neuron. The morphological response of
microglia to stimulation was assessed by assigning cells
to 3 sub categories; Type 1 microglia which exhibit ex-
tended processes and an elongated cell body, Type 2
microglia with retracted processes and a rounded cell
body and Type 3 microglia exhibiting a very small,
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rounded cell body. 5 random fields of at least 200 cells
were counted per coverslip per condition and the per-
centage of each subtype was determined [35].
Live/Dead Assay Cell viability in WT and Ppt1−/− astro-
cyte cultures was assessed using a Live/Dead kit (Invitro-
gen) according to the manufacturer’s instructions.
Briefly, Live/Dead dye was diluted in DMSO and added
30 min prior to fixation of cultures 24, 48 or 72 h after
plating astrocytes onto coverslips. Astrocyte cultures
were then co-stained with GFAP and 10 random fields
were counted per coverslip.
Calcium Measurements Astrocytes were plated in
μ-Slide 8 well imaging dishes (Sigma) at 1.5cells/cm2.
Cells were loaded with 5 μM Fura2-AM (Teflabs) in
DMEM with 1% BSA and 0.025% Pluronic acid F127 for
1 h at room temperature, before being washed in im-
aging buffer (HBSS, 1 mM HEPES and 1 mM MgCl2)
and left at room temperature for 10 min. Intracellular
Ca2+ concentrations and responses were recorded with a
Colibri LED microscope system, using an Axiocam Mrm
CCD camera and Axiovision software (Version 4.7) with
an additional physiology module for live cell Ca2+ imaging
(Zeiss). Recordings of the Ca2+ probe baselines were taken
prior to agonist addition in order to provide basal Ca2+
measurements of the cell, and all agonist-induced re-
sponses were compared at peak height.
Release of endoplasmic reticulum (ER) Ca2+ was mea-
sured after addition of 5 μM of thapsigargin (Sigma).
Lysosomal Ca2+ release was measured using a method
adapted from [26]. Following with 5 μM ionomycin (Cal-
biochem) to prevent release from intracellular Ca2+
stores, the addition of 10 μM nigericin (Sigma) was used
to induce Ca2+ release from the lysosome. To examine
store operated Ca2+ entry, ER Ca2+ release was triggered
as described, and following return to the baseline, 1 mM
Ca2+ was added to the imaging medium. In order to trig-
ger Ca2+ plasma membrane influx, 100 μM ATP (Sigma)
was added after astrocytes were loaded with Fura2-AM
in imaging buffer and 1 mM CaCl2.
Protein Secretion To compare pharmacologically stim-
ulated cytokine secretion by WT and Ppt1−/− glia, super-
natant was collected from mixed glial, astrocyte and
microglial cultures and analysed with ELISA kits (Signo-
sis, Santa Clara, CA). A mouse oxidative stress ELISA
kit was selected to quantify microglial cytokine secretion
based on previous evidence that Ppt1−/− neurons exhibit
signs of oxidative stress [49], a custom mouse cytokine
ELISA kit was used to examine cytokine secretion by as-
trocytes based on pilot cytokine data generated in our la-
boratory, and cytokine secretion in mixed glial cultures
was assessed with a mouse cytokine ELISA kit (all kits
from Signosis). All these experiments were carried out
according to the manufacturer’s instructions.
Statistical analysis All data were collected into Micro-
soft Excel spreadsheets and analysed in Graphpad Prism.
All data are presented as mean ± SEM. A student’s
t-test was used to analyse data between two groups,
data sets with more than two groups were analysed
with a one-way ANOVA using Bonferroni’s correction.
All experiments were repeated in triplicate, using
three technical replicates per experiment, unless
otherwise stated. Data were considered statistically
significant if p ≤ 0.05, p values are marked * if p ≤ 0.05, ** if
p ≤ 0.01 and *** if p ≤ 0.001.
Results
Ppt1−/− astrocytes exhibit an activated phenotype under
basal conditions
Astrocyte activation can be observed as early as 3 months
of age in Ppt1−/− mice, and progressively becomes more
pronounced and widespread towards the later stages of
the disease [23, 29]. Before comparing the in vitro phe-
notypes of Ppt1−/− and WT astrocytes we first defined
the cellular composition of our astrocyte cultures. One
week after plating, over 99% of DAPI positive cells in
astrocyte cultures of either genotype were positive for the
astrocyte marker glutamine synthetase (GS) (WT: 99.2%
GS + ve, 0.71% CD68 + ve, and 0% O4 + ve; Ppt1−/−: 99.6%
GS + ve, 0.35% CD68 + ve, and 0% O4 + ve).
Using GFAP as a marker whose increased expression
is associated with astrocyte activation, we first compared
the morphology of astrocytes in cultures derived from
mice of both genotypes, under both basal and simulated
conditions (Fig. 1A). Under basal conditions the morph-
ology of cultured Ppt1−/− astrocytes was more heteroge-
neous than that seen in WT cultures, with many
GFAP-positive astrocytes appearing larger in Ppt1−/−
cultures (Fig. 1A). The proportion of GFAP-positive cells
under basal unstimulated conditions was significantly
higher in Ppt1−/− astrocyte cultures than in WT cultures
(Fig. 1B). Cultures were then stimulated with LPS and
IFNγ, to examine astrocyte response to a standardized
pharmacological stimulus [35]. Although the proportion
of GFAP-positive astrocytes was significantly upregulated
in WTcultures after both 24 h and 48 h of stimulation, no
further changes in the proportion of GFAP-positive astro-
cytes were observed in Ppt1−/− cultures upon stimulation
(Fig. 1B). These data reveal that although more Ppt1−/− as-
trocytes express GFAP under basal culture conditions, this
proportion does not increase further upon stimulation
with LPS/ IFNγ, as it does with WTastrocytes.
To quantify the morphological responses of astrocytes to
stimulation, we measured astrocyte soma size (Fig. 1C).
Under basal conditions, Ppt1−/− astrocytes exhibited a
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markedly and significantly larger soma size than WTastro-
cytes. However, upon stimulation for 24 or 48 h Ppt1−/−
astrocytes dramatically reduced their cell body size, a ty-
pical response of cultures astrocytes to pharmacological
stimulation, so that they were now of a similar size to
stimulated WT astrocytes at either time point (Fig. 1C).
Taken together these data reveal that although appearing
morphologically different to WT astrocytes under basal
conditions, Ppt1−/− astrocytes still respond robustly to
pharmacological stimulation by changing their shape.
Increased secretion of soluble factors by Ppt1−/−
astrocytes
Increased secretion of specific soluble proteins is a hall-
mark of astrocyte activation (Lucas et al., 2006), and we
used an ELISA kit to investigate the release of soluble
factors following stimulation in our astrocyte cultures.
No significant differences in the release of TNFα, IL-1α,
IFNγ, FGFB, or EGF were observed between WT and
Ppt1−/− astrocytes following 24 h exposure to LPS and
IFNγ (Fig. 2). However, significantly higher amounts of
IL-4, SCF and VEGF were released by Ppt1−/− astrocytes
(35.98 ± 17.80%; 10.74 ± 3.98%; 5.90 ± 4.16% more, re-
spectively) than by WT astrocytes (− 14.12 ± 9.39%; − 1.68
± 3.47%; − 12.61 ± 3.02% less, respectively) (Fig. 2). Not
only does this provide further evidence that Ppt1−/− astro-
cytes respond differently to stimulation than their WT
counterparts, but is also in marked contrast to data ob-
tained from Cln3−/− astrocytes which exhibit reduced
release of soluble factors following stimulation [35]. Fur-
thermore, lactate secretion from Ppt1−/− astrocytes was
significantly increased 1.4 fold (p < 0.05, data not shown)
under basal conditions, which may point towards the pos-
sibility of mitochondrial dysfunction as shown in aging
and prematurely aging mice [39], with mitochondrial fai-
lure and a shift in transcriptional activities of lactate dehy-
drogenases resulted in increased brain lactate levels.
Mitochondrial dysfunction is closely linked with oxidative
stress and has previously been reported in other forms of
the NCLs ([34]; Jalanko et al., 2009).
Ppt1−/− astrocyte survival is impaired in vitro
There are fewer cells that stain positively for GS or
S100β in 6 month old Ppt1−/− mice [29], suggesting that
Fig. 1 Ppt1 deficient (Ppt1−/−) astrocytes exhibit a reactive phenotype. A Wild type (WT) and Ppt1−/− Astrocytes were stained for glial fibrillary
associated protein (GFAP) to assess GFAP expression and astrocyte morphology under basal and stimulated (LPS/IFNγ) conditions after 24 and 48 h.
Immunostaining for GFAP (red) revealed the morphology of Ppt1−/− and WT astrocytes under basal and stimulated conditions, with Ppt1−/− astrocytes
exhibiting a large flattened morphology (white arrow) under basal conditions. B A higher percentage of Ppt1−/− astrocytes stained positively for (GFAP)
under basal conditions, with no significant upregulation following stimulation. C The soma size or spread of Ppt1−/−astrocytes was much larger under
basal conditions than in WT astrocytes, however was reduced following stimulation for 24 and 48 h. (Data shown as Mean ± SEM using a one way
ANOVA, n = 3). Scale bar = 50 μm
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Fig. 2 Expression of SCF, VEGF and IL-4 was significantly higher in Ppt1 deficient (Ppt1−/−) astrocytes after stimulation. Supernatant was collected
from wild type (WT) and Ppt1−/− astrocyte cultures kept under basal and stimulated conditions for 24 h. Cytokine release was assessed using an
ELISA kit (Signosis) and calculating changes in expression between basal and stimulated conditions. No statistically significant changes were
observed in the secretion of Epidermal growth factor (EGF), Interferon γ (IFNγ), Tumour necrosis factor α (TNFα), Expression of Basic flbroblast
growth factor (FGFb) and Interleukin 1-α (IL1α). Stem cell factor (SCF), Vascular endothelial growth factor (VEGF) and Interleukin-4 (IL-4) was
significantly higher in Ppt1−/− astrocyte cultures following stimulation than in WT cultures. (Data shown as Mean ± SEM using a t-test, n = 3)
Fig. 3 Impaired Survival of Ppt1 deficient (Ppt1−/−) astrocytes. A lower cell number was observed in Ppt1−/− astrocyte cultures than in wild type (WT)
cultures, due to decreased cell survival. a Under basal and stimulated conditions the number of Ppt1−/−astrocytes per coverslip was markedly lower
than in WT cultures as indicated by significantly reduced counts of cells stained with the nuclear marker DAPI. b At 24, 48 and 72 h following seeding
onto coverslips cell death was significantly higher in Ppt1−/− astrocyte cultures than in their WT counterparts. c A live/dead cell death marker (red)
revealed the increased presence of dying cells in Ppt1−/−astrocyte cultures stained for GFAP (green), compared to those derived from WT mice. (Data
shown as Mean ± SEM using a one way ANOVA, n = 3). Scale bar = 50 μm
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astrocyte survival may be impaired in CLN1 disease in
the later stages of disease progression. These data
prompted us to investigate Ppt1−/− astrocyte survival in
our cultures, and during our immunofluorescence stain-
ing experiments, we noticed fewer DAPI-stained nuclei
in Ppt1−/− astrocyte cultures under all basal and stimu-
lated conditions. Counts of the number of DAPI-stained
cells in these Ppt1−/− astrocyte cultures confirmed they
were significantly reduced in number (Fig. 3a). However,
no significant differences in the percentage of proliferat-
ing cells was observed in Ppt1−/− astrocyte cultures (data
not shown), and as such could not account for signifi-
cantly reduced number of astrocytes in these cultures.
Consequently, a Live/Dead kit was used to investigate
cell survival 24, 48 and 72 h after plating the cells onto
coverslips (Fig. 3b, c). Across all time points, signifi-
cantly more astrocytes were positive for both GFAP and
for the Live/Dead marker in Ppt1−/− cultures, indicative
of them undergoing cell death (24.83 ± 1.49%; 25.87 ±
1.78%; 34.99 ± 4.66%, at 24, 48 and 72 h respectively)
compared to their WT counterparts (7.95 ± 1.08%; 10.57
± 2.10%; 14.09 ± 1.08% at 24, 48 and 72 h respectively)
(Fig. 3b, c). These data reveal that Ppt1−/− astrocyte sur-
vival is markedly impaired in vitro, suggesting an inher-
ent vulnerability of Ppt1−/− astrocytes rather than any
defect in their ability to proliferate. Although these tis-
sue culture data for impaired astrocyte survival are con-
sistent with our previous histological evidence from the
Ppt1−/− brain [29], it remains unclear what the extent
and nature of astrocyte death may be in vivo, and it will
be important to resolve this issue.
Ppt1- /−astrocytes display abnormal Ca2+ signalling with
increased cytoplasmic Ca2+ levels
De-regulated Ca2+ signalling has been implicated in the
pathogenesis of several neuro-degenerative disorders, in-
cluding several lysosomal storage disorders (reviewed in
Lloyd-Evans, 2016). After the endoplasmic reticulum
(ER), the lysosome represents an important intracellular
Ca2+ store [6, 26]. Thapsigargin is an inhibitor of the
sarco/endoplasmic reticulum ATPase (SERCA) that at
high concentrations induces Ca2+ release from the ER by
blocking uptake and uncovering the ER leak channels
(Chandrachud et al., 2015). Nigericin is a H+/K+ iono-
phore that will release Ca2+ from both lysosomes and
mitochondria by collapsing the H+ gradient [26]. How-
ever, prior pre-treatment with ionomycin results in Ca2+
release from all intracellular stores apart from lysosomes,
where its action is blocked by the lysosomal glyocaylix,
meaning that resultant effects of nigericin on Ca2+ release
are solely from lysosomal stores [26].
The base-line level of cytoplasmic Ca2+ was signifi-
cantly elevated in Ppt1- /− astrocytes (Fig. 4a), suggesting
that they are more stressed than their WT counterparts,
and this likely caused by the significantly higher num-
ber of spontaneous Ca2+ release events that we ob-
served in the Ppt1−/− astrocytes (data not shown).
Stimulation of Ppt1- /− and WT astrocytes with thap-
sigargin revealed no difference between genotypes in the
level of Ca2+ released from the ER (thapsigargin, Fig. 4b)
or from lysosomes (ionomycin/nigericin, Fig. 4c) or, sug-
gesting Ca2+ release from these intracellular stores was
unaffected in Ppt1- /− astrocytes. ATP mediated intracellu-
lar Ca2+ elevation was significantly lower in Ppt1- /− astro-
cytes (Fig. 4d), and following thapsigargin depletion of the
ER there was a small, but significant, increase in store
operated Ca2+ entry in Ppt1- /− astrocytes (Fig. 4e). Taken
together these data suggest that Ppt1- /− astrocytes display
marked abnormalities in Ca2+ signalling with elevated
levels of both spontaneous Ca2+ release events and resting
basal cytoplasmic Ca2+ that may be related to their pro-
nounced survival defect.
Ppt1−/− microglia exhibit an activated morphological
phenotype in vitro
Alongside activation of astrocytes, microglial activa-
tion is also evident in Ppt1−/− mice as early as three
months of age with marked up-regulation of CD68
[27]. We first defined the cellular composition of our
microglial cultures. One week after plating microglial
cultures showed over 99% of DAPI stained cells
expressed CD68 (99.1 and 99.8% CD68 + ve in WT
and Ppt1−/−, respectively; with only 0.89 and 0.14%
being GFAP+ve). To assess the in vitro properties of
Ppt1−/− microglia, we first assessed their ability to
undergo morphological transformation following
pharmacological stimulation with LPS, a response that
is impaired in Cln3 deficient microglia [35]. Following
stimulation with LPS, WT and Ppt1- /− microglial cul-
tures were stained with CD68 and α-tubulin, and as
described previously cells were classified into 3 mor-
phological subcategories: type 1 cells – microglia with
extended processes (non-activated); type 2 cells –
microglia with retracted processes (partly activated);
type 3 cells– rounded cells with a small soma (fully
activated) [35].
Under basal conditions, the vast majority of
CD68-positive microglia in WT cultures exhibited a
bipolar or rod-like morphology (Fig. 5A). Quantita-
tively these Type 1 cells were the predominant micro-
glial subtype in WT cultures (Fig. 5B). In contrast, far
fewer Type 1 cells were present in Ppt1−/− microglial
cultures under basal conditions (Fig. 5B), with the
majority of CD68-positive microglia exhibiting a
rounded Type 2 morphology (Fig. 5C). As expected,
following LPS stimulation WT microglia rounded up,
and Type 2 microglia became the prevailing cell type
in these cultures (Fig. 5C). Little change in Ppt1−/−
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Fig. 4 (See legend on next page.)
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microglial morphology was observed following stimu-
lation for 6 or 24 h, potentially because these mutant
microglia already appeared morphologically to be acti-
vated (Fig. 5A, C). Very few Type 3 microglia were
observed in either WT or Ppt1−/− microglial cultures
(data not shown), consistent with previous observa-
tions that prolonged stimulation is required to fully
activate microglia to become small and rounded
[35]. Taken together these data suggest that Ppt1−/−
microglia appear morphologically to be already
activated under basal conditions and do not dramat-
ically alter their morphology any further when stim-
ulated pharmacologically.
IL-1β secretion is increased in stimulated Ppt1−/−
microglia
Oxidative stress has previously been suggested to play a
role in poor cellular health in patient derived primary
Ppt1−/− deficient fibroblasts [49]. Because microglia are im-
plicated in mediating the effects of oxidative stress [7, 13],
(See figure on previous page.)
Fig. 4 Ppt1 deficient (Ppt1−/−) astrocytes exhibit changes in Ca2+ homeostasis. Ca2+ measurements were completed 48 h after seeding of wild type
(WT) and Ppt1−/− astrocytes under basal conditions to assess changes in Ca2+ homeostasis. Representative Ca2+ traces shown for WT (blue) and Ppt1−/−
(red) astrocytes (b-e). (a) Baseline Ca2+ levels measured with Fura2 dye (340/380 nm) were significantly higher in Ppt1−/−astrocytes. (b) No statistically
significant differences were detected between WT and Ppt1−/− astrocytes in Ca2+ released from endoplasmic reticulum Ca2+ stores, mediated by 5 μM
thapsigargin. c Lysosomal Ca2+ release, triggered by 10 μM nigericin was also not significantly altered in Ppt1−/−astrocytes. d ATP (100 μM) mediated
Ca2+ influx was significantly lower in Ppt1−/−astrocytes than in their WT counterparts. e Store-operated Ca2+ entry, triggered by 5 μM thapsigargin
followed by 1 mM CaCl2, was significantly higher in Ppt1
−/−astrocytes than in WT astrocytes
Fig. 5 Ppt1 deficient (Ppt1−/−) microglia appear morphologically more activated under basal conditions. To assess microglial activation, we first
needed to define their morphology. Type 1 or ‘resting’ microglia exhibit a rod shaped morphology. Type 2 or activated microglia exhibit a round soma
and withdrawn processes. Microglial morphology was visualised by staining for CD68 and α-tubulin and 5 random fields were counted per coverslip.
α-tubulin was used to assess microglial morphology since CD68 was observed to be more concentrated in the soma and processes were not well
visualised using this antibody in these images microglial morphology was visualised with α-tubulin, as CD68 is more concentrated in the soma and
processes were not well visualised with this antigen. Morphology was assessed under basal conditions and after stimulation with LPS for 6 and 24 h. A
Ppt1−/− microglia appeared morphologically more activated under basal conditions, as more cells with rounded cell bodies were present. Following
treatment with LPS, WT microglia assumed a more reactive morphology. Scale bar = 50 μm. B A higher percentage of Type 1 microglia were present
in WT microglial cultures than in Ppt1−/−microglial cultures, and the percentage of Type 1 microglia was reduced following stimulation. C More Type 2
microglia were present under basal conditions in Ppt1−/− cultures. The percentage of Type 2 microglia increased following stimulation with LPS after 6
and 24 h in WT microglial cultures. (Data shown as Mean ± SEM using a one way ANOVA, n = 3)
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we investigated the release of soluble proteins typic-
ally associated with oxidative stress from Ppt1−/−
microglia. ELISA assays of these proteins revealed no sig-
nificant differences in the release of TNFα, TGFβ, IL-1α,
IL-6, IL-10, IL-12 or MCP-1 from WTand Ppt1−/− micro-
glial cultures (Additional file 1: Figure S1). However, the
release of IL-1β was significantly higher in Ppt1−/− cul-
tures (5.48 ± 4.32%) following 24 h stimulation than in
WT cultures (− 8.41 ± 2.04%), suggesting that Ppt1−/−
microglia may adapt a more inflammatory phenotype
upon stimulation than WT microglia (Additional file 1:
Figure S1). It will be important to provide Ppt1−/− micro-
glia with an oxidative stress stimulus and determine if the
expression of these factors is further altered.
Ppt1−/− neurons display impaired survival of interneurons
and morphological defects
Before defining the impact of Ppt1 deficient astrocytes
or microglia upon neurons, we first assessed neuronal
culture composition. In neuronal cultures > 82% of cells
stained positively for Map2 (16% GFAP positive, 0.3%
CD68 positive) after 7 days, and > 93% Map2 positive
(5% GFAP positive, 3% CD68 positive) after 14 days. We
then compared the survival and morphology of cultured
primary cortical neurons derived from WT and Ppt1−/−
mice (Fig. 6a).
Inhibitory neurons are amongst the most vulnerable
cells in Ppt1−/− mice [3], and although there was little
difference in overall cell number between Ppt1−/− and
WT neuronal cultures after 7 DIV (data not shown), the
percentage of inhibitory neurons stained with a cocktail
of antibodies against the interneuron markers parvalbu-
min, calbindin and calretinin was significantly lower in
Ppt1−/− cortical neuron cultures (4.79 ± 1.41% vs 9.94 ±
1.10% WT) (Fig. 6b). Subsequently, after 14 DIV a sig-
nificantly higher proportion of cells in Ppt1−/− neuronal
cultures stained positive for cleaved caspase 3 (6.61 ±
1.13% vs 2.49 ± 0.45% WT), suggesting their impaired
longer-term survival in vitro (Fig. 6c). We also quantified
neuronal morphology as an indicator of in vitro de-
velopment and neuronal health, and first revealed that
the soma size of Map2-positive neurons was signifi-
cantly smaller in Ppt1−/− cultures at all time points
(Fig. 6d).
Assessing neurite complexity (Fig. 7), revealed that at
7, 9, and 14 DIV the mean neurite length was signifi-
cantly shorter in Ppt1−/− vs. WT neurons (Fig. 7a), as
was the length of their longest neurite, (Fig. 7b) which
by 14 DIV is typically the axon [12, 14, 46]. Changes in
neurite morphology were readily apparent in Map2
stained cultures (Fig. 7c), but quantitative analysis
revealed specific arborization defects. Although the
Fig. 6 Ppt1 deficient (Ppt1−/−) neuronal cultures exhibit altered culture composition and impaired survival. a To analyse neuronal cell death and
visualise neuronal morphology, WT and Ppt1−/−neuronal cultures were stained for Map2 and CC3. Pictures of 14 day old cultures stained with
nuclear marker DAPI (blue), showing more Map2 positive cells (green) in Ppt1−/−neuronal cultures labelled with CC3 (red) that in WT cultures.
Arrows indicate CC3/ DAPI positive cells in WT cultures and Map2/CC3/DAPI positive cells in Ppt1−/− neuronal cultures. Scale bar = 50 μm. b
Significantly fewer neurons were positively stained for parvalbumin/calretinin/calbindin in Ppt1−/− neuronal cultures, indicating that fewer
inhibitory neurons are present than in WT neuronal cultures after 7 days in vitro. c The percentage of CC3 positive cells did not differ between
WT and Ppt1−/−neuronal cultures after 9DIV, but was significantly higher in Ppt1−/−cultures after 14DIV. d Ppt1−/−neurons stained for Map2 had
significantly smaller soma sizes after 7, 9 and 14 days in vitro (DIV) compared to WT neurons. (Data shown as Mean ± SEM using a one way
ANOVA, n = 3)
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average number of primary neurites was similar between
neurons of both genotypes (Fig. 7d), Ppt1−/− neurons
had significantly fewer secondary (Fig. 7e) or tertiary
(Fig. 7f ) neurites at 7 DIV. Taken together these data
suggest that Ppt1−/− neurons not only show impaired
morphology in vitro, suggesting they are in poor health,
but also display a moderate impairment in their survival.
It will now be important to study neuronal arborization
in vivo, to see whether these findings are corroborated
in Ppt1-deficient mice.
Co-cultures reveal the impact of Ppt1 deficiency on
cellular interactions
To assess the impact of Ppt1−/− astrocytes or microglia
on each other, or WT and Ppt1−/− neurons, we grew
these cell types together in different combinations (e.g.
astrocytes with microglia, neurons with astrocytes, neu-
rons with microglia, neurons with both astrocytes and
microglia), using the morphological phenotypes defined
above and survival as outcome measures as outcome
measures. As such, for co-cultures were stained with
Map2 and CC3, soma size as well as neurite length and
complexity were measured and the percentage of cells
undergoing apoptosis was determined. Where appropri-
ate, microglia were labelled with CD68 and astrocytes
with GFAP.
Detrimental impact of Ppt1−/− astrocytes upon neuron
morphology
We first assessed different co-culture combinations of
astrocytes and neurons of different genotypes, which
Fig. 7 Ppt1 deficient (Ppt1−/−) neurite outgrowth is impaired. Wild type (WT) and Ppt1−/− neuronal cultures were stained with MAP2 to visualise
neuronal processes and DAPI to label all nuclei. Neurite length was measured using ImageJ. a Mean neurite length is significantly shorter in Ppt1−/−
neuronal cultures than in WT cultures after 7, 9 and 14 days in vitro (DIV). b The length of the longest neurites, assumed to be the axon is significantly
reduced in Ppt1−/−neurons compared to WT neurons after 7, 9 and 14 DIV. c Ppt1−/− neurons stained for Map2 appear to have shorter neurites than
their WT counterparts and appear less complex. d The number of primary neurites did not differ between WT and Ppt1−/− neuronal cultures after
7 days in vitro (DIV). e Ppt1−/− neurons had significantly fewer secondary neurites than their WT counterparts after 7 DIV. f Significantly fewer tertiary
neurites were present in Ppt1−/−neuronal cultures. (Data shown as Mean ± SEM using a one way ANOVA, n = 3). Scale bar = 50 μm
Lange et al. Acta Neuropathologica Communications  (2018) 6:74 Page 11 of 21
revealed obvious effects upon neuron survival and
morphology (Fig. 8a). Quantifying these changes, cell
death in neuron-astrocyte co-cultures, as revealed by CC3
immunostaining, was significantly greater when Ppt1−/−
astrocytes were present (Fig. 8b), either in combination
with WT neurons (13.41 ± 2.18%) or Ppt1−/− neurons
(14.03 ± 2.61%). This cell death was predominantly of as-
trocytes rather than neurons, as there was little correlation
between the overall percentage of CC3-positive cells, and
those positive for both CC3 and the neuron marker Map2
(data not shown). Less cell death was evident in Ppt1−/−
neuron/WT astrocyte co-cultures (Fig. 8b), but this differ-
ence was not statistically significant.
In contrast, Ppt1−/− astrocytes appeared to have a
detrimental impact on neuronal health, as judged by
neuronal morphology. When grown with Ppt1−/− as-
trocytes, WT neuronal soma size was significantly re-
duced (Fig. 8c), with decreased mean neurite length
Fig. 8 (See legend on next page.)
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(Fig. 8d), but not of the longest neurite, probably the
axon (Fig. 8e). These effects were more pronounced
after 7 days in co-culture, when WT neurons started
resembling Ppt1−/− neurons morphologically (Fig. 8a).
Although Ppt1−/− astrocytes did not adversely impact
Ppt1−/− neuron soma size after 7 days in co-culture
(Fig. 8c), the neurites of these Ppt1−/− neurons were
not only significantly shorter than in Ppt1−/− neuronal
cultures (50.41 ± 2.71 μm vs 65.02 ± 2.51 μm) (Fig. 8d, e),
but also had fewer secondary neurites (4.2 ± 0.11vs 5.69 ±
0.4 secondary neurites) (Fig. 8g). In contrast, WT astro-
cytes appeared to improve Ppt1−/− neurite outgrowth
(80.02 ± 3.31 μm) (Fig. 8d-e), but had no discernible im-
pact on Ppt1−/− neurite complexity (Fig. 8f-h).
The overall impact of Ppt1−/− astrocytes appeared to be
primarily detrimental to neuronal health, adversely affecting
their morphology rather than triggering their death. Al-
though the morphological defects of Ppt1−/− neurons can
be partially restored by WT astrocytes, their survival is not
improved, which suggests an intrinsic defect in Ppt1−/−
neuronal survival, despite any possible cross-correction ef-
fect of Ppt1 enzyme secreted from WTastrocytes.
Detrimental impact of Ppt1−/− microglia upon neuron
survival
We next grew co-cultures of microglia with neurons, in
order to assess the impact of these cell types from mice of
different genotypes upon each other and revealed a pro-
found impact of Ppt1−/− microglia upon neuron survival
(Fig.9a). Cell death as indicated by CC3 staining appeared
significantly higher in Ppt1−/− neuron/ Ppt1−/− microglial
co-cultures than in WT neuron/ Ppt1−/− microglial
co-cultures, Ppt1−/− neuronal cultures and Ppt1−/− neuron/
WT microglial co-cultures (Fig. 9a) There were significantly
more double- labelled CC3- and Map2-positive cells in
Ppt1−/− neuron/ Ppt1−/− microglial co-cultures (16.05 ±
1.57%) than in WT neuron/ Ppt1−/− microglial cultures
(6.31 ± 1.19%) (Fig. 9b). While these data suggest a direct
cytotoxic effect of Ppt1−/− microglia upon neurons, a com-
bined effect of Ppt1−/− microglia with the small number of
astrocytes also present in these cultures cannot be ruled out.
We next investigated neuronal morphology in these
co-cultures and saw no significant effects of either WT or
Ppt1−/− microglia upon the soma size of neurons of either
genotype (Fig. 9c). No detrimental effects of Ppt1−/− micro-
glia could be observed on neurite outgrowth (Fig. 9d-e), or
neurite complexity (Fig. 9f-h). However, in Ppt1−/− neuron/
WT microglia co-cultures there were more secondary (8.1
± 0.29 vs 5.8 ± 0.08 Ppt1−/− neurons) and tertiary neurites
(2.33 ± 0.2 vs 1.41 ± 0.15 Ppt1−/− neurons) (Fig. 9g-h) than
in Ppt1−/− neuron cultures, and these neurites were longer
(74.96 ± 0.84 μm Ppt1−/− neuron vs. 87.37 ± 3.35 μm
Ppt1−/−/ WT co-culture) (Fig. 9d-e), suggesting a positive
influence of WT microglia upon neurite outgrowth and
complexity, perhaps by their secretion of Ppt1 enzyme.
Overall, these data reveal that, compared to Ppt1−/−
astrocytes, Ppt1−/− microglia exert less of an influence
upon neuronal morphology, but exert a significant nega-
tive effect upon the survival of Ppt1−/− neurons with
much less of an impact upon WT neurons. As such,
Ppt1−/− microglia do not appear to be intrinsically
neurotoxic, but it appears that Ppt1−/− neurons may
simply be more vulnerable to their influence.
Astrocytes drive microglial activation in Ppt1−/− mixed
glial cultures
Mixed glial cultures containing both astrocytes and
microglia of either genotype were grown to examine
whether the presence of other glial cells may improve or
exacerbate the phenotypes exhibited by either cell type
in monocultures. The presence of microglia appeared to
have little impact on Ppt1−/− astrocytes, as the percent-
age of GFAP-expressing cells remained significantly
(See figure on previous page.)
Fig. 8 Wild Type (WT) astrocytes ameliorate morphological defects in Ppt1 deficient (Ppt1−/−) neurons. a WT and Ppt1−/− astrocytes and neurons were
cultured together for 2 or 7 days, and stained with MAP2 (green) and cleaved caspase 3 (CC3, red) to examine cell survival and neuronal morphology. b
After both 2 and 7 days in culture, the percentage of CC3 expressing cells was significantly higher in both WT and Ppt1−/− co-cultures when grown with
Ppt1−/− astrocytes. c After both 2 and 7 days in culture, soma size in all Ppt1−/− culture conditions was significantly smaller than in WT monocultures, and
WT neuron/WT astrocyte co-cultures. Although Ppt1−/− astrocytes had little effect upon Ppt1−/− neuronal soma size, WT neuron soma size was significantly
reduced when grown with Ppt1−/−astrocytes after 2 and 7 days in culture. d After 2 days in co-culture, the mean neurite length was shorter in Ppt1−/−
neurons under all conditions. Following 7 days in co-culture, Ppt1−/− astrocytes had a detrimental impact on both WT and Ppt1−/− neurite outgrowth,
whereas WT astrocytes improved neurite outgrowth in Ppt1−/− neurons. e Axon length in all Ppt1−/− cultures was significantly shorter than in WT neuron
and WT neuron/WT astrocyte co-cultures after 2 days. After 7 days, Ppt1−/− axon length was significantly reduced in the presence of Ppt1−/− astrocytes,
whereas WT astrocytes significantly improved axon growth. f The number of primary neurites was significantly lower in in all Ppt1−/− cultures as well as WT
neuron/ Ppt1−/− astrocyte cultures. g Secondary neurite number was significantly reduced in WT neuron/ Ppt1−/− astrocyte cultures, Ppt1−/− neuron
cultures Ppt1−/− neuron/WT astrocyte and Ppt1−/− neuron/ Ppt1−/− astrocyte co-cultures compared to WT neuron cultures and WT neuron/WT astrocyte
cultures. Secondary neurite number remained significantly lower in Ppt1−/− neuron/ Ppt1−/− astrocyte cultures than in WT neuron/ Ppt1−/− astrocyte
cultures, Ppt1−/− astrocyte cultures and Ppt1−/− neuron/ Ppt1−/− astrocyte cultures. h The number of tertiary neurites was significantly lower in WT neuron/
Ppt1−/− astrocyte cultures, Ppt1−/− neuron cultures, Ppt1−/− neuron/WT astrocyte and Ppt1−/− neuron/ Ppt1−/−astrocyte co cultures than in WT neuronal
cultures and WT neuron/WT astrocyte cultures. (Data shown as Mean ± SEM using a one-way ANOVA, n= 3, # represents significant difference to WT
neuron cultures, + represents significant difference to WT neuron/WT astrocyte cultures)
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higher in Ppt1−/− cultures under basal conditions and
after exposure to LPS alone than in WT cultures
(Fig. 10a). Similarly, Ppt1−/− astrocyte soma size in these
mixed glial cultures was consistently significantly larger
than that of WT astrocytes, until stimulated with LPS
and IFNγ, after which Ppt1−/− astrocyte cell body size
decreased dramatically (Fig. 10b), as we had seen in
astrocyte monocultures (Fig. 1b). Significantly fewer cell
nuclei were counted in Ppt1−/− mixed glial cultures
(408.1 ± 28.89 vs 720.7 ± 43.19 WT) (Fig. 10c),
Fig. 9 Ppt1 deficient (Ppt1−/−) microglia trigger Ppt1−/− neuronal death. Wild type (WT) and Ppt1−/− neurons and microglia were cultured
together 7 days, and stained with MAP2 and cleaved caspase 3 (CC3) to examine cell survival and neuronal morphology. a The percentage of
CC3 expressing cells was statistically significantly higher in Ppt1−/−neuron/ Ppt1−/− microglial co-cultures than in all other cultures. In contrast
Ppt1−/−microglia had a smaller impact on WT neuronal survival. b The percentage of Map2/CC3 expressing cells was highly variable within all
cultures, although was significantly higher in Ppt1−/− neuron/ Ppt1−/−microglial co-cultures than in WT neuron and WT neuron/WT microglial
cultures. c Neuronal soma size was significantly smaller for Ppt1−/− neurons across all co-cultures, compared to the soma size of WT neurons in
either WT monocultures or WT neuron/WT microglial co-cultures. Neuronal soma size was somewhat reduced in WT neuron/ Ppt1−/− microglial
co-cultures, but this difference was not statistically significant. d Ppt1−/− microglia do not have a detrimental effect on Ppt1−/−or WT mean neurite
length. However, the presence of WT microglia had a beneficial impact in increasing Ppt1−/−neurite length. e Axon length in WT or Ppt1−/−
cultures was unaffected by Ppt1−/−microglia, and the apparently beneficial impact of WT microglia upon axon length was not as pronounced as
on mean neurite length. f The number of primary neurites was significantly lower across all Ppt1−/− cultures. g Secondary neurite number was
significantly reduced in Ppt1−/−neuron cultures, Ppt1−/− neuron/WT microglia and Ppt1−/− neuron/ Ppt1−/− microglia co-cultures compared to WT
neuron cultures and WT neuron/WT microglial cultures. A trend towards increased secondary neurite number was observed in Ppt1−/− neuron/
WT microglial cultures. h The number of tertiary neurites was significantly lower in Ppt1−/− neuron cultures, Ppt1−/−neuron/WT microglial and
Ppt1−/− neuron/ Ppt1−/−microglial cultures than in WT neuronal cultures and WT neuron/WT microglial cultures. (Data shown as Mean ± SEM
using a one way ANOVA, n = 3; # represents significant difference to WT neuron cultures, + represents significant difference to WT neuron/WT
microglia cultures)
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suggesting that the presence of WT microglia does not
improve Ppt1−/− astrocyte survival.
The phenotypes seen in Ppt1−/− microglial monocul-
tures also persisted in mixed astrocyte:microglial cul-
tures. Under basal conditions, Type 1 microglia (63.99 ±
1.39%) were the predominant cell type in WT cultures
(Fig. 10d), which transformed into rounded Type 2 acti-
vated microglia following stimulation (81.53 ± 4.03%
LPS, 78.82 ± 6.74% LPS/IFNγ) (Fig. 10e). Under all con-
ditions, activated Type 2 microglia (75.70 ± 3.17% basal;
96.02 ± 1.84% LPS; 95.31 ± 1.91% LPS/IFNγ) were the
prevailing type of microglia present in Ppt1−/− microglial
cultures (Fig. 8e), however the percentage of activated
Type 2 microglia was significantly higher in mixed astro-
cyte:microglial cultures than in microglial monocultures
(Fig. 10e). Furthermore, following stimulation with LPS
only or LPS and IFNγ, the percentage of Type 2 micro-
glia significantly increased in Ppt1−/− mixed astrocyte:-
microglial cultures (Fig. 10f), which was not observed in
cultures of microglia alone. These data suggest that
Ppt1−/− astrocytes may drive microglial activation, and
also induce a greater microglial response following
pharmacological stimulation.
Neuron/astrocyte/microglial co-cultures
The presence of even some Ppt1−/− astrocytes appears to
influence morphological measures of microglial activa-
tion (Fig. 10), and may also potentially influence any
negative impact of microglia (Fig. 9). Therefore, we
hypothesised that growing mixed cultures that contain
Fig. 10 Ppt1 deficient (Ppt1−/−) astrocytes drive microglial activation. Ppt1−/− and wild type (WT) cultures were maintained as mixed glial (astrocyte
and microglial) cultures to examine whether monoculture phenotypes were maintained under basal and stimulated (LPS or LPS/IFNγ) conditions. a
Under basal conditions, the proportion of cells expressing the astrocyte marker glial fibrillary acidic protein (GFAP) expression was higher in Ppt1−/−
mixed glial cultures than in their WT counterparts. GFAP expression did not increase in WT or Ppt1−/− mixed glial cultures following addition of LPS,
but did increase in WT following stimulation with LPS/IFNγ. b Under basal conditions, compared to WT cultures, Ppt1−/− astrocytes exhibited a larger
cell body size, which was decreased dramatically in response to exposure to LPS/IFNγ but not LPS only. c The mean total cell number as indicated by
DAPI staining was statistically significantly lower in Ppt1−/− mixed glial cultures. d The percentage of Type 1 (resting, elongated) microglia was
significantly higher in WT cultures under basal conditions than in Ppt1−/− mixed glial cultures. e The percentage of Type 2 (activated, rounded)
microglia was higher in Ppt1−/− mixed glial cultures under basal conditions. In both WT and Ppt1−/− mixed glial cultures the percentage of Type 2
microglia was increased following stimulation with LPS, or with LPS/IFNγ. f Ppt1−/− microglia appear morphologically more activated in mixed glia
cultures than in microglial cultures, as indicated by a significantly higher percentage of Type 2 microglia under both basal and stimulated (LPS)
conditions in mixed glial cultures. (Data shown as Mean ± SEM using a one way ANOVA, n = 3)
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proportionately more astrocytes than microglia, a
situation that may more closely reflect the composition
if the brain in vivo [20], might result in the most
detrimental environment for neurons. This appeared to
be the case with progressively more CC3-positive cells
being observed in these co-cultures with time (Fig. 11),
with a corresponding negative influence upon neuronal
morphology (Fig. 11a).
After 7 days in co-culture, cell death levels were at
their highest in Ppt1−/− neuron/ Ppt1−/− mixed glial
cultures (22.67 ± 2.17% of cells CC3 + ve) (Fig. 11b), a
significant increase compared to cell death after 2 days
of co-culturing Ppt1−/− neurons with Ppt1−/− mixed glia
(14.05 ± 2.33% of cells CC3 + ve), which was comparable
to that in WT neuron/ Ppt1−/− mixed glial co-cultures.
In contrast, there appeared to be a moderate protective
effect of WT astrocytes resulting in decreased cell death
in Ppt1−/− neuron/WT mixed glial cultures (5.58 ± 0.32%
of cells CC3 + ve) (Fig. 11b), perhaps as a result of cross
correction by Ppt1 enzyme secreted by these WT cells.
Fig. 11 (See legend on next page.)
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Exploring effects upon neuronal morphology revealed
that the soma size of Ppt1−/− neurons was not affected by
the presence of either WT or Ppt1−/− mixed glia, and
remained significantly smaller than their WT counterparts
(Fig. 11c). However, when WT neurons were grown with
Ppt1−/− mixed glia, their neuronal soma size was signifi-
cantly reduced, suggesting a detrimental impact of these
Ppt1 deficient astrocytes and microglia upon neuronal
health (Fig. 11c). Indeed, Ppt1−/− astrocytes and microglia
also had a pronounced and rapid impact upon WT average
neurite length (Fig. 11d-e), which was significantly shorter
after only 2 days in co-culture (64.25 ± 1.24 μm vs WT neu-
rons 84.72 ± 3.13 μm). Although some growth in WT neur-
ite length was apparent with continued time in culture,
average neurite length remained shorter after 7 days of
co-culture in WT neuron/ Ppt1−/− mixed glial cultures
(76.70 ± 4.01 μm) vs. WT/WT cultures (96.59 ± 0.80 μm).
The combined presence of Ppt1−/− astrocytes and microglia
also significantly impacted neurite complexity with signifi-
cant reductions in the average number of primary (4.48 ±
0.09 vs 5.61 ± 0.28 WT neurons, Fig. 11f), secondary (6.07
± 0.45 vs 10.08 ± 0.44 WT neurons, Fig. 11g) and tertiary
neurites in WT neurons (1.21 ± 0.12 vs 3.29 ± 0.35 WT
neurons, Fig. 11h). In contrast, the presence of WT astro-
cytes and microglia produced no significant improvements
in Ppt1−/− neuronal soma size (Fig. 11c), neurite outgrowth
(Fig. 11d-e) or complexity (Fig. 11f-h).
Taken together, these data suggest that the presence of
both Ppt1−/− astrocytes and microglia has the most signifi-
cant detrimental effects upon neurons, not just upon their
morphology, but also upon the survival of both WT and
Ppt1−/− neurons. WT astrocytes and microglia were not
capable of rescuing the pronounced defects of Ppt1−/−
neurons, providing further evidence that these neurons
are intrinsically more vulnerable than WT neurons.
Discussion
The purpose of undertaking this tissue culture study was
not to replicate disease progression in the Ppt1 deficient
brain, but rather to assess intrinsic defects in Ppt1−/−
glial biology. Indeed, in addition to detailing defects in
the morphology and survival of neurons, this study is
the first to characterize Ppt1−/− glia in vitro. Our data re-
veal that not only do Ppt1−/− microglia and astrocytes
exhibit a range of abnormal phenotypes, they also appear
capable of harming neurons, especially if these neurons
are Ppt1 deficient. Whilst Ppt1−/− astrocytes predo-
minantly affect neuronal morphology, the presence of
Ppt1−/− microglia alone was enough to impact neuron
survival, a negative influence that was greater if both
Ppt1−/− astrocytes and Ppt1−/− microglia were present,
resulting in pronounced neuron loss. These data suggest
that glial cells are more affected by Ppt1 deficiency than
previously anticipated, and this may directly influence
neuron survival in CLN1 disease and it will be important
to explore this also occurs in vivo. However, as discussed
below, these defects in Ppt1 deficient glia are quite dis-
tinct from those we recently reported in similar experi-
ments in CLN3 disease [35], another member of this
group of disorders in which a negative influence of func-
tionally compromised glia upon neuronal survival is evi-
dent. Taken together, these data provide further evidence
that although these disorders broadly share similar fea-
tures, they may differ markedly in how individual cell
types are impacted by disease.
Effects of Ppt1 deficiency upon glial biology
Compared to the morphologically attenuated glial activa-
tion that is evident in CLN3 disease [35], mouse models
of CLN1 disease exhibit much more pronounced and
early onset activation of both astrocytes and microglia in
(See figure on previous page.)
Fig. 11 Ppt1 deficient (Ppt1−/−) astrocyte/microglia interactions escalate cell death in Ppt1−/− neuron/ Ppt1−/− mixed glial cultures after prolonged co-
culturing. a Wild type (WT) and Ppt1−/− neurons and mixed glia (astrocytes and microglia) were cultured together for 2 and 7 days and stained with MAP2
and cleaved caspase 3 (CC3) to examine cell survival and neuronal morphology. Cells were stained with neuronal marker Map2 (green), cell death marker
CC3 (red) and nuclear stain DAPI (blue). After 7 days in co-culture, more CC3 positive cells were observed in WT neuron/ Ppt1−/− mixed glial co-cultures
and Ppt1−/− neuron/ Ppt1−/− mixed glial co-cultures. Scale bar = 50 μm. b The percentage of CC3 positive cells was significantly higher in WT neuron/
Ppt1−/− mixed glial co-cultures, and Ppt1−/− neuron/ Ppt1−/− mixed glial co-cultures after both 2 and 7 days. After 7 days, the percentage of CC3 positive
cells had significantly increased within Ppt1−/− neuron/ Ppt1−/− mixed glial co-cultures. c Soma size across Ppt1−/− cultures was smaller than in WT and WT
neuron/WT mixed glial co-cultures after both 2 and 7 days in culture. WT neuron size was significantly reduced following the addition of Ppt1−/− mixed
glia at both time points. d After both 2 and 7 days in culture, mean neurite length was shorter across all Ppt1−/− cultures than in WT monocultures or WT
neuron/WT mixed glial co-cultures. WT neurite length was significantly reduced in the presence of Ppt1−/− mixed glia after 2 and 7 days in culture. Ppt1−/−
neurite length was also somewhat reduced after 7 days in co-culture with Ppt1−/− mixed glia. e Ppt1−/− axon length was consistently shorter than that of
WT neurons, and although WT axon length was somewhat reduced in WT neuron/ Ppt1−/− mixed glial co-cultures, this was not statistically significant. f
The number of primary neurites was significantly lower in WT neuron/ Ppt1−/− mixed glial cultures, as well as in all Ppt1−/− cultures. g Secondary neurite
number was significantly reduced in WT neuron/ Ppt1−/− mixed glial cultures, Ppt1−/− neuron cultures, Ppt1−/− neuron/WT mixed glial and Ppt1−/− neuron/
Ppt1−/− mixed glial co-cultures compared to WT neuron cultures and WT neuron/WT mixed glial cultures. Secondary neurite number remained significantly
lower in Ppt1−/− neuron and Ppt1−/− neuron/Ppt1−/− mixed glial cultures than in WT neuron/Ppt1−/− mixed glial cultures. h The number of tertiary neurites
was significantly lower in WT neuron/Ppt1−/− mixed glial cultures, Ppt1−/− neuron cultures, Ppt1−/− neuron/WT mixed glial and Ppt1−/− neuron/Ppt1−/−
mixed glial cultures than in WT neuronal cultures and WT neuron/WT mixed glial cultures. (Data shown as Mean ± SEM using a one way ANOVA,
n = 3; # represents significant difference to WT neuron cultures, + represents significant difference to WT neuron/WT microglia cultures)
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the same CNS regions that later display the most neuron
loss. This includes the thalamocortical system [23], cere-
bellum [29], and long before these events occur in the
brain this glial activation is also evident at all levels of
the spinal cord [43]. These reactive events are accom-
panied by a pronounced upregulation of chemokines
and cytokines in vivo [29], that can be normalized by a
combination of brain directed gene therapy and
anti-inflammatory drugs [28]. Our data demonstrate that
cultured Ppt1−/− astrocytes are very responsive to
pharmacological stimulation (Figs. 1), and Ppt1−/−
microglia appear morphologically more activated even
under basal unstimulated conditions (Fig. 5). This is quite
different to the properties of cultured Cln3−/− astrocytes
and microglia that both respond slowly and incompletely
[35], mirroring the relative extent of morphological trans-
formation of these cell types with disease progression in
murine CLN1 and CLN3 diseases in vivo [23, 35, 37, 38].
Another marked phenotypic difference between glia iso-
lated from mouse models of these two forms of NCLs is
the reduced secretion of chemokines and cytokines by
Cln3−/− astrocytes and microglia in culture [35], compared
to the elevated secretion of a subset of these factors by
Ppt1−/− astrocytes (Fig. 2) and microglia (Additional file 1:
Figure S1), data that mirrors in vivo findings for much
broader elevation of such factors [29]. Any comparison
between in vitro and in vivo studies must be made with
caution. However, there are differences between these ex-
pression profiles in terms of which chemokines are upreg-
ulated. These may reflect the markedly different ages of
the mice when these studies were performed, the inherent
differences in a tissue culture environment and the living
brain, as well as the pharmacological stimulation used in
the current in vitro study.
Another fundamental difference between data from
Cln1 and Cln3 glia, is that compared to the disruption
of intermediate filaments seen in Cln3−/− astrocytes
[35], the current study found no evidence for any
similar cytoskeletal defects in Ppt1−/− astrocytes (data
not shown). Taken together, these data emphasize that
although glia from both of these mouse models of
NCL display a variety of abnormal phenotypes in
culture, and that these consistently affect astrocytes
more than microglia, the nature and extent of these
glial defects differ markedly between CLN1 and CLN3
disease.
One of the most striking findings of the current study
is the compromised survival of Ppt1−/− astrocytes in all
culture conditions, a phenotype not exhibited by Cln3−/−
astrocytes in vitro [35]. It will be important to determine
if this vulnerability of Ppt1−/− astrocytes is related to ab-
normal calcium signalling properties that they display
(Fig.4), but it might be expected that these raised cyto-
plasmic calcium levels would contribute to their death.
It will be crucial to determine if Ppt1−/− astrocyte sur-
vival is also impaired in vivo to a similar extent that we
have observed in vitro. Although there is already
evidence for fewer astrocytes expressing S100β and
glutamine synthetase in Ppt1−/− mice during the later
stages of the disease [29], which points towards a loss of
these astrocyte populations in vivo, this issue is yet to be
fully resolved. Our in vitro findings do provide further
corroborative evidence for an inherent vulnerability of
Ppt1−/−astrocytes, and this would be expected to ad-
versely impact neurons and their survival during CLN1
disease progression. However, the exact mechanisms
underlying such cell-specific vulnerability of astrocytes
remain unclear and will need to be investigated in subse-
quent in vivo studies.
Effects of Ppt1 deficiency upon neurons
CLN1 disease is perhaps the most profoundly neurode-
generative form of NCL, with near total cortical neuron
loss at autopsy [18]. However, the mechanisms by which
a deficiency in a de-palmitoylating lysosomal enzyme
leads to this remarkably dramatic neuron loss remain
unclear. Previous studies culturing neurons derived from
Ppt1−/− mice surprisingly did not reveal any overt defect
in their survival, or firing properties, but did find alter-
ations in the synaptic vesicle pool size [47]. These are
suggestive of an early stage synaptic pathology, and
Ppt1−/− mice do go on to display progressive changes in
synaptic organization within the thalamocortical system
[24]. Our data in this study provide new evidence that
Ppt1−/− cortical neurons show compromised survival in
our culture conditions (Fig. 6c), display a markedly
smaller cell soma (Fig. 6d) and compromised neurite
organization in vitro, that involves secondary and ter-
tiary neurites rather than those arising directly from the
soma (Fig. 7d-f ). This neuron loss was most pronounced
for GABAergic interneurons (Fig. 6b), consistent with in
vivo data from these Ppt1−/− mice [3, 23]. Taken to-
gether, these data reveal that Ppt1 deficiency does not by
itself result in the same profound extent of neuron loss
seen in vivo, suggesting that other non-neuron-intrinsic
mechanisms may operate to influence neurodegenera-
tion in this disorder.
Assessing the glial contribution to neuron loss
There is an increasing body of evidence that glial activation
and/or dysfunction have an active role in the pathogenesis
of several neurodegenerative disorders [1, 36, 40, 44]. Al-
though not necessarily themselves instigators of neurode-
generation, any disruption of the normal support functions
served by astrocytes or microglia may plausibly lead to
neuron dysfunction or loss. The concept that glial cells can
contribute to disease severity and accelerate its progression
is perhaps most advanced in ALS and Parkinson disease,
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but it is becoming apparent this principle also extends to
several lysosomal storage disorders. Lysosomal dysfunction
and disrupted autophagy were thought to lead to the toxic
role of astrocytes in multiple sulfatase deficiency, with the
suggestion that a genetic defect in astrocytes alone was
sufficient to drive the disease [11]. Microglial activation
has also been suggested to contribute adversely to the
pathogenesis in various LSDs including MPSI, MPSIIIB,
Sandhoff disease and GM2 gangliosidosis [22, 33, 48], but
the extent to which this happens in the NCLs is less clear.
The close correlation between the sites where early lo-
calized glial activation occurs in every form of NCL, and
the extent of subsequent neuron loss [9, 34], has always
begged the question of whether these events may be
mechanistically related to one another. So far, the role of
glia in these disorders has been investigated in most
depth in CLN3 disease, and there is recent evidence for
a negative influence of Cln3 deficient microglia [51] and
astrocytes [4] upon neurons. We have recently extended
these observations, using very similar primary culture
and co-culture systems used in the present study [35].
This approach revealed a variety of defects in the biology
of Cln3−/− microglia and astrocytes, and when grown in
co-cultures, these dysfunctional glia harmed healthy
neurons and resulted in the death of Cln3−/− neurons
[35]. These data prompted us to investigate whether
there was any influence of Ppt1−/− astrocytes and micro-
glia upon neuron health in CLN1 disease.
Despite the marked differences in the phenotypes dis-
played in vitro by Ppt1−/− glia (this study) and Cln3−/−
glia [35], a consistent feature is that astrocytes and
microglia deficient in either gene exert a negative influ-
ence of upon neuronal morphology and survival. The
relative contributions of either Cln3−/− astrocytes or
microglia to these processes are yet to be defined, as are
the underlying mechanisms, but the current study has
provided the first insights into the negative influence of
glia in CLN1 disease. Our data reveals that this adverse
impact varies between cell types, with Ppt1−/− astrocytes
only exerting a moderate influence on neuronal morph-
ology (Fig. 8), whereas Ppt1−/− microglia are capable of
inducing the death of neurons (Fig. 9), especially if these
neurons are themselves Ppt1 deficient. These differences
likely reflect how each of these cell-types are compro-
mised by Ppt1 deficiency, and it will be important to in-
vestigate these mechanisms by transcriptional profiling.
Whatever the underlying mechanisms may be, this ad-
verse influence appeared to be exacerbated when both
Ppt1−/− astrocytes and Ppt1−/− microglia were present
(Fig. 11). This is consistent with recent data suggesting
that under certain conditions microglia may prime astro-
cytes to become neurotoxic [25]. However, the specific
factors implicated in this priming mechanism were not
all upregulated by Ppt1−/− microglia, and it may be that
different mechanisms operate in CLN1 disease. However,
data from our co-cultures of Ppt1−/− astrocytes and
Ppt1−/− microglia together (without any neurons
present) suggest that these mutant astrocytes appear to
drive these Ppt1−/− microglia to become further acti-
vated (Fig. 10). Indeed, it seems plausible that the toxic
effect of Ppt1−/− microglia (Fig. 9) may be exacerbated
by the consequence of impaired Ppt1−/− astrocyte func-
tion and/or survival to create conditions that promote
neuron loss, perhaps via the increased release of IL-1β
from microglia (Additional file 1: Figure S1), but this
awaits experimental verification. Previous data had sug-
gested astrocyte activation was beneficial in this disorder
(Macauley et al., 2011), since disease progression was ac-
celerated in GFAP−/−/Vimentin−/−/Ppt1−/− mice in which
glial activation is genetically suppressed. This is in
marked contrast to data from our co-culture systems
that suggest a negative influence of Ppt1−/− astrocytes
upon neuron health (Figs. 8, 11), and it will be essential
to validate these effects in vivo.
In order to address such issues, we are already gener-
ating mice in which Ppt1 can be inactivated in a cell
type-specific manner. Such approaches would normally
be complicated by the release of Ppt1 enzyme from gen-
etically unmodified cells to cross correct the cell type in
which Ppt1 has been inactivated. However, the gener-
ation of mice expressing a biologically active membrane
tethered Ppt1 enzyme that is not secreted [42] provides
important proof of principle for this strategy, which will
be employed in our future studies. Nevertheless, this in
vitro study has provided novel evidence for a greater ex-
tent of dysfunction in Ppt1−/− glial cells than was previ-
ously anticipated and highlights the need for targeting
glial cells in developing therapies for CLN1 disease. Gene
therapy using newer generations of adeno-associated vi-
ruses has shown increasing efficacy, especially if these are
targeted simultaneous to the brain and spinal cord [43].
These vectors predominantly transduce neurons, and
these would secret Ppt1 enzyme to cross correct Ppt1 de-
ficient glia within the CNS and correct their defects [10,
15, 45]. Regardless of such cross-correction, the adminis-
tration of anti-inflammatory compounds to Ppt1−/− mice
provides additional benefit above gene therapy alone [28],
and greater therapeutic efficacy may yet be provided by
testing other drugs of this type. In a clinical setting, such
neuroimmunomodulatory or anti-inflammatory ap-
proaches may be of use either before gene therapy can be
administered or as an adjunct to gene therapy.
The NCLs have been grouped together traditionally on
the basis of certain broadly similar clinical and patho-
logical themes, but as new data emerge it is becoming
evident that this is an oversimplification. It is clear that
cultured astrocytes and microglia generated from CLN1
(this study) and CLN3 mice [35] are dysfunctional and
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exert a negative influence upon neuron health and may
ultimately contribute to neurodegeneration. However, as
the CLN1 data in this study reveal, the nature of these
events differs markedly between these two major forms
of NCL. Perhaps this is not surprising given that these
two forms of NCL are caused by mutations in genes that
encode such different types of proteins, one a lysosomal
hydrolase (CLN1/PPT1) and the other a transmembrane
protein whose function remains obscure (CLN3). Never-
theless, these findings have direct implications for our
understanding of the cellular pathogenesis of these dis-
orders and in this respect, it will be important to extend
these studies to other forms of NCL.
Additional file
Additional file 1: Figure S1. Expression of Interleukin-1β is increased
following stimulation of Ppt1 deficient (Ppt1−/−) microglia. Supernatant
was collected from wild type (WT) and Ppt1−/− microglial cultures kept
under basal and stimulated conditions for 24 h. Release of cytokines
linked to oxidative stress was assessed using an ELISA kit (Signosis) and
calculating changes in expression between basal and stimulated
conditions. Secretion of Tumor necrosis factor α (TNFα), Transforming
Growth Factor β (TGFβ), Monocyte Chemoattractant Protein-1 (MCP-1),
Interleukin (IL)-1α, IL-6, IL-10 and IL-12 was not statistically significant be-
tween WT and Ppt1−/− microglia, however secretion of IL-1β was signifi-
cantly higher in Ppt1−/− cultures. (Data shown as Mean ± SEM using a t-
test, n = 3). (TIF 2444 kb)
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